↓ Skip to main content

Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data

Overview of attention for article published in The Pharmacogenomics Journal, February 2020
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#8 of 854)
  • High Attention Score compared to outputs of the same age (96th percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news
7 news outlets
blogs
1 blog
twitter
7 X users

Citations

dimensions_citation
29 Dimensions

Readers on

mendeley
72 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data
Published in
The Pharmacogenomics Journal, February 2020
DOI 10.1038/s41397-020-0162-5
Pubmed ID
Authors

Nita A. Limdi, Larisa H. Cavallari, Craig R. Lee, William B. Hillegass, Ann M. Holmes, Todd C. Skaar, Maria Pisu, Chrisly Dillon, Amber L. Beitelshees, Philip E. Empey, Julio D. Duarte, Vakaramoko Diaby, Yan Gong, Julie A. Johnson, John Graves, Shawn Garbett, Zilu Zhou, Josh F. Peterson

X Demographics

X Demographics

The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 72 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 72 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 9 13%
Student > Ph. D. Student 7 10%
Researcher 5 7%
Student > Postgraduate 5 7%
Other 4 6%
Other 13 18%
Unknown 29 40%
Readers by discipline Count As %
Medicine and Dentistry 19 26%
Biochemistry, Genetics and Molecular Biology 5 7%
Pharmacology, Toxicology and Pharmaceutical Science 4 6%
Nursing and Health Professions 3 4%
Economics, Econometrics and Finance 2 3%
Other 8 11%
Unknown 31 43%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 58. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 October 2021.
All research outputs
#676,120
of 24,003,070 outputs
Outputs from The Pharmacogenomics Journal
#8
of 854 outputs
Outputs of similar age
#18,072
of 462,135 outputs
Outputs of similar age from The Pharmacogenomics Journal
#1
of 24 outputs
Altmetric has tracked 24,003,070 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 854 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 462,135 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.